DexCom, Inc. (DXCM)

$77.63

+3.10 (+4.16%)
Rating:
Recommendation:
Buy
Symbol DXCM
Price $77.63
Beta 1.065
Volume Avg. 3.66M
Market Cap 30.470B
Shares () -
52 Week Range 66.8925-164.8625
1y Target Est -
DCF Unlevered DXCM DCF ->
DCF Levered DXCM LDCF ->
ROE 9.84% Neutral
ROA 4.17% Neutral
Operating Margin -
Debt / Equity 130.99% Buy
P/E 158.75 Strong Buy
P/B 55.03 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DXCM news


Mr. Kevin Sayer
Healthcare
Medical Devices
NASDAQ Global Select

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.